|Group||Scientific Advisory Board|
Dr. Déglon received her education, including a Ph.D. in Biochemistry, at the University of Lausanne, Switzerland. She held several research positions at the Gene Therapy Center in Lausanne, at the Salk Institute in San Diego, California, and at the Federal Polytechnic Institute of Lausanne, Switzerland where she developed gene therapy approaches for neurodegenerative diseases.
In 2003, she joined the French Atomic Energy Commission (CEA) as Research Director and Deputy Director of MIRCen, a pre-clinical imaging platform for drug, cell and gene therapy. She is currently associate Professor in the department of clinical Neurosciences at the Lausanne University Hospital (CHUV).
Dr. Déglon’s research interests include the development of viral-based genetic models of neurodegenerative diseases, the treatment of neurodegenerative diseases from cell transplantation to gene therapy, and investigation of the central nervous system by means of functional and molecular imaging techniques.